Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Rating of “Moderate Buy” from Analysts

Context Therapeutics Inc. (NASDAQ:CNTX) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $6.1667.

CNTX has been the topic of a number of research reports. Maxim Group reduced their target price on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Wall Street Zen lowered shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Friday, July 17th.

Context Therapeutics Stock Down 1.9%

Shares of NASDAQ CNTX opened at $0.60 on Friday. The firm’s 50-day simple moving average is $1.12 and its 200 day simple moving average is $1.95. The company has a market cap of $55.59 million, a price-to-earnings ratio of -1.44 and a beta of 1.75. Context Therapeutics has a 12-month low of $0.55 and a 12-month high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. On average, equities analysts expect that Context Therapeutics will post -0.39 earnings per share for the current year.

Institutional Investors Weigh In On Context Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Octagon Capital Advisors LP acquired a new position in shares of Context Therapeutics during the first quarter valued at $13,755,000. Millennium Management LLC bought a new stake in Context Therapeutics during the 4th quarter worth about $3,824,000. Marshall Wace LLP lifted its position in Context Therapeutics by 7,153.7% during the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after purchasing an additional 2,557,448 shares during the period. Seven Fleet Capital Management LP bought a new position in shares of Context Therapeutics in the 1st quarter valued at about $500,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Context Therapeutics by 58.8% in the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after purchasing an additional 188,202 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.